Programs

VAXX has broad capabilities to develop new products for major preventative and therapeutic indications to the clinical proof-of-principle stage. One of the company's most advanced program comprises the development and evaluation of a novel norovirus virus-like particle (VLP) preventative vaccine called noroVAXX®. This vaccine has been subjected to extensive preclinical development and is currently undergoing manufacturing process optimization.

VAXX is also exploring application of its technologies to the development of novel vaccines for chronic and infectious diseases.